Capital City Trust’s Gilead Sciences GILD Stock Holding History

Capital City Trust’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$365K	Sell	2,888 -264	-8%	-$34.8K	0.08%	102
2026 Q1	$439K	Buy	+3,152	New	+$441K	0.1%	91
2019 Q2	–	Sell	-4,346	Closed	-$283K	–	98
2019 Q1	$283K	Buy	4,346 +116	+3%	+$7.71K	0.12%	87
2018 Q4	$265K	Buy	4,230 +120	+3%	+$8.39K	0.12%	90
2018 Q3	$317K	Buy	4,110 +41	+1%	+$3.1K	0.13%	90
2018 Q2	$288K	Sell	4,069 -60	-1%	-$4.24K	0.12%	89
2018 Q1	$311K	Hold	4,129	–	–	0.13%	89
2017 Q4	$296K	Sell	4,129 -133	-3%	-$10.1K	0.12%	93
2017 Q3	$302K	Hold	4,262	–	–	0.12%	88
2017 Q2	$302K	Buy	4,262 +418	+11%	+$27.8K	0.12%	88
2017 Q1	$261K	Buy	3,844 +535	+16%	+$37.6K	0.1%	92
2016 Q4	$237K	Buy	+3,309	New	+$246K	0.09%	97

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital City Trust's GILD Position: Q2 2026 in Review

Capital City Trust reduced its Gilead Sciences (GILD) stake by 8.4% in Q2 2026, selling an estimated $34.8K and leaving 2,888 shares worth $365K. The position accounts for 0.08% of the portfolio, ranked #102.

Capital City Trust first reported a position in GILD in Q4 2016 and has held it in 12 quarters since. The position peaked at $439K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Capital City Trust held 2,888 shares of Gilead Sciences worth $365K as of Q2 2026.
Capital City Trust sold 264 Gilead Sciences shares in Q2 2026, an estimated $34.8K.
Gilead Sciences made up 0.08% of Capital City Trust's portfolio in Q2 2026, its #102 holding.
Capital City Trust first reported a position in Gilead Sciences in Q4 2016 and has held it in 12 quarters since.
Capital City Trust's Gilead Sciences position peaked at $439K in Q1 2026.
2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Capital City Trust's 13F filing for Q2 2026, filed 4 Aug 2026.